FindTrial
Sign In

Study on the efficacy of sequential therapy with alprostadil in the treatment of cerebral small vessel disease

Study on the efficacy of sequential therapy with alprostadil in the treatment of cerebral small vessel disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011209
Enrollment
Unknown
Registered
2017-04-21
Start date
2017-04-25
Completion date
Unknown
Last updated
2017-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral small vessel disease

Interventions

Group 1:Aspirin 100mg/d
Group 2:Aspirin 100mg/d+Alprostadil Injection 20ug/d 10days
Group 2:Aspirin 100mg/d+Beraprost Sodium Tablets 40ug, tid, 3months
Group 2:Aspirin 100mg/d

Sponsors

Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: aged more than 50 years, with hypertension, diabetes; with acute or old lacunar infarctionwith or without cognitive dysfunction; with or without leukoencephalopathy, with or without gait abnormality.

Exclusion criteria

Exclusion criteria: Intracerebral hemorrhage, subarachnoid hemorrhage, macrovascular disease, embolic cerebrovascular disease, AD and other types of dementia; intolerant to aspirin.

Design outcomes

Primary

MeasureTime frame
Clinical symptom;Neuropsychological scale;imaging data;—

Countries

China

Contacts

Public ContactYUN XU

Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing

xuyun20042001@aliyun.com+86 025 83105208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026